Cutler Group LP Fennec Pharmaceuticals Inc. Transaction History

Cutler Group LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$5.71 - $8.54 $793 - $1,187	139 New	139 $1,000
Q3 2021 Oct 26, 2021	SELL	$6.51 - $9.62 $651 - $961	-100 Closed	0 $0
Q2 2021 Jul 19, 2021	SELL	$5.96 - $7.85 $596 - $785	-100 Reduced 50.0%	100 $0
Q1 2021 Apr 26, 2021	BUY	$6.21 - $8.68 $621 - $868	100 Added 100.0%	200 $1,000
Q3 2020 Oct 27, 2020	SELL	$5.19 - $10.17 $3,633 - $7,119	-700 Reduced 87.5%	100 $0
Q2 2020 Jul 22, 2020	BUY	$5.43 - $9.39 $4,344 - $7,512	800 New	800 $6,000

14.9M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $104M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.